Viatris, Inc. (VTRS)
NASDAQ:VTRS
Want to see VTRS full AI Analyst Report?
VTRS Stock Chart & Stats
$14.68
>-$0.01(-0.04%)
At close: 4:00 PM EST
$14.68
>-$0.01(-0.04%)
Day’s Range― - ―
52-Week Range$8.63 - $17.53
Previous CloseN/A
Volume2.11M
Average Volume (3M)11.55M
Market Cap
$17.90B
Enterprise Value$30.86B
Total Cash (Recent Filing)$1.80B
Total Debt (Recent Filing)$14.34B
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 10, 2026EPS Estimate
0.61Next Dividend Ex-DateN/A
Dividend Yield3.99%
Share Statistics
EPS (TTM)-0.26
Shares Outstanding1,164,552,600
10 Day Avg. Volume8,660,972
30 Day Avg. Volume11,545,796
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.99
Price to Sales (P/S)1.02
P/FCF Ratio7.52
Enterprise Value/Market Cap1.72
Enterprise Value/Revenue2.12
Enterprise Value/Gross Profit6.16
Enterprise Value/Ebitda12.03
Forecast
1Y Price Target
$17.50Price Target Upside19.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)2.46
Revenue Forecast (FY)$14.78B
Bulls Say, Bears Say
Bulls Say
Cash Generation & LiquidityManagement reports robust cash generation and more than $2.5 billion available for deployment, with Q1 cash generation of $348M (or ~$459M adjusted). That durable cash cushion supports debt service, M&A, buybacks, dividends and reinvestment, reducing refinancing risk and enhancing financial optionality over the medium term.
Greater China Growth AccelerationGreater China delivered an 18% YoY acceleration and management raised its 2026 growth expectation. Structural channel gains (e‑commerce more than doubled) and commercial investment point to a sustained revenue tailwind in a large market, materially improving geographic diversification and growth runway for the next several quarters.
Pipeline And Complex Generic LaunchesNew product launches and complex generics (including an Abilify Maintena generic and multiple pending FDA decisions) are contributing meaningful incremental revenue and typically carry higher margins. Successful execution on these regulatory catalysts can shift product mix toward differentiated, less commoditized offerings and sustain revenue and margin improvement.
Bears Say
Weak/negative ProfitabilityTrailing‑twelve‑month net income remains negative and operating profitability is thin and volatile. Persistent lack of consistent GAAP profits limits internal funding for growth and returns, suppresses ROE, and forces reliance on cash reserves or external financing to fund strategic initiatives, constraining long‑term capital allocation flexibility.
Multi‑year Revenue Drift DownRevenue has trended lower over multiple years, indicating structural pressure on scale and pricing power. A prolonged top‑line drift erodes manufacturing and SG&A leverage, makes margin recovery harder, and increases sensitivity to any single launch or market, limiting durable earnings growth absent sustained new product success or market share gains.
Competitive, Supply And Regulatory Execution RiskThe business faces structural headwinds from intense generics competition, periodic supply constraints in lower‑margin portfolios, and timing/regulatory uncertainty for key approvals. These factors pressure margins, can delay revenue recognition from launches, and increase execution risk for the company's multi‑product growth plan over the medium term.
Viatris News
VTRS FAQ
What was Viatris, Inc.’s price range in the past 12 months?
Viatris, Inc. lowest stock price was $8.63 and its highest was $17.53 in the past 12 months.
What is Viatris, Inc.’s market cap?
Viatris, Inc.’s market cap is $17.90B.
When is Viatris, Inc.’s upcoming earnings report date?
Viatris, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 52 days.
How were Viatris, Inc.’s earnings last quarter?
Viatris, Inc. released its earnings results on May 07, 2026. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.502 by $0.088.
Is Viatris, Inc. overvalued?
According to Wall Street analysts Viatris, Inc.’s price is currently Undervalued.
Does Viatris, Inc. pay dividends?
Viatris, Inc. pays a Quarterly dividend of $0.12 which represents an annual dividend yield of 3.99%. See more information on Viatris, Inc. dividends here
What is Viatris, Inc.’s EPS estimate?
Viatris, Inc.’s EPS estimate is 0.61.
How many shares outstanding does Viatris, Inc. have?
Viatris, Inc. has 1,164,552,600 shares outstanding.
What happened to Viatris, Inc.’s price movement after its last earnings report?
Viatris, Inc. reported an EPS of $0.59 in its last earnings report, beating expectations of $0.502. Following the earnings report the stock price went up 9.032%.
Which hedge fund is a major shareholder of Viatris, Inc.?
Currently, no hedge funds are holding shares in VTRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viatris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (19.21% Upside)
$17.50 (19.21% Upside)
Blogger Sentiment
Neutral
VTRS Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $283.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.17%
12-Months-Change
Fundamentals
Return on Equity
-1.97%
Trailing 12-Months
Asset Growth
-4.26%
Trailing 12-Months
Company Description
Viatris, Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
VTRS Company Deck
VTRS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call portrayed solid operational performance and momentum: top-line revenue growth (3%), strong adjusted EBITDA expansion (10%), sizable China acceleration (+18%), meaningful pipeline progress with multiple upcoming regulatory catalysts, and robust cash flexibility (> $2.5B). These positives were tempered by regional softness (Europe, JANZ), supply constraints in lower-margin generics/ARV, ongoing regulatory timing uncertainty, and policy risk in China. On balance, the positives (broad-based execution, margin control, late-stage pipeline momentum and financial flexibility) outweigh the lowlights.View all VTRS earnings summariesVTRS Net sales Breakdown
64.45% Brands
35.55% Generics
VTRS Stock 12 Month Forecast
Average Price Target
$17.50
▲(19.21% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Perrigo Company
―
Teva Pharmaceutical
―
ANI Pharmaceuticals
―
Amneal Pharmaceuticals
―
Ownership Overview
0.28% Insiders
26.74% Mutual Funds
21.00% Other Institutional Investors
23.93% Public Companies and
Individual Investors